Research projects
Cima Universidad de Navarra
-
Translational OncologyActive
51-2021 Caloric restriction as a tool to enhance the efficacy and minimize the toxicity of immunotherapy for lung cancer.
Cima Principal Investigator: Daniel Ajona Martínez-PoloFunder: Gobierno de Navarra / Departamento de SaludAward year 2021 -
Oncogenes and Effector TargetsActive
PLEC2021-007959 MYCOMBIO. Use of MYC inhibition to overcome immunotherapy resistance in KRAS-driven NSCLC with diverse mutational profiles.
Cima Principal Investigator: Silvestre Vicent CambraFunder: Ministerio de Ciencia e InnovaciónAward year 2021 -
Translational OncologyActive
IDEAS211016AJON Short-term starvation to enhance antitumor activity and attenuate side effects of lung cancer immunotherapy side effects of immunotherapy for lung cancer.
Cima Principal Investigator: Daniel Ajona Martínez-PoloFunder: Asociación Española contra el CáncerAward year 2021 -
Immunology and ImmunotherapyActive
PLEC2021-008094 CARPanTu. Targeting the tumor microenvironment to improve CAR-T cell based immunotherapy in pancreatic canceronment to improve CAR-T cell b
Cima Principal Investigator: Juan José LasarteFunder: Ministerio de Ciencia e InnovaciónAward year 2021 -
Heart FailureActive
MINERVA II Project: cardIoreNal pERsonalized cardIoreNal Medicine in NaVArrA
Cima Principal Investigator: Arantxa González Miqueo [SP]Funder: Gobierno de NavarraAward year 2021 -
Medicinal ChemistryActive
MicroBiomics: Applications of the multi-omic study of the microbiota to the development of innovative biotechnological solutions in the area of health care.
Cima Principal Investigator: Antonio Pineda LucenaFunder: Gobierno de NavarraAward year 2021 -
Non-coding RNA in hepatocarcinoma and other liver diseasesActive
BLANCA Project: Genomic technology to generate a cancer vaccine
Cima Principal Investigator: Mª Purificación Fortes Alonso [SP]Funder: Gobierno de NavarraAward year 2021 -
Active
-
Heart FailureActive
ICI20/00011 Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments (bB-ECHO).
Cima Principal Investigator: Arantxa González Miqueo [SP] [SP]Funder: Instituto de Salud Carlos III -
Heart FailureActive
PI20/01319 Identification of a biomarker-based molecular fingerprint of heart failure with chronic kidney disease. Potential mechanistic, prognostic and therapeutic implications
Cima Principal Investigator: Susana Ravassa Albéniz [SP]Funder: Instituto de Salud Carlos III